Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging
- Written by PR Newswire
![]() |
MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET[1] agent, TLX250-CDx (Zircaix®[2]...








